No Data
Hualan Co., Ltd.: Report for the third quarter of 2024
While Institutions Invested in Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SZSE:301093) Benefited From Last Week's 19% Gain, Retail Investors Stood to Gain the Most
Hualan Shares (301093.SZ): Some of the raised funds for investment projects are planned to be postponed.
Granolink reported on September 26 that Hualan Shares (301093.SZ) announced that on September 26, 2024, the company held the twenty-seventh meeting of the fifth board of directors and the twenty-fourth meeting of the fifth board of supervisors, and reviewed and approved the "Proposal on the Delay of Some Raised Funds Investment Projects". Based on the current implementation progress and actual situation of the raised funds investment projects (hereinafter referred to as the "investment projects"), and without any changes in the main body, implementation method, investment purpose, and investment scale of the investment projects, the company, after careful study, decided to "Automated, asia vets Factory Renovation Project" and "Expansion of Pre
Hualan Co., Ltd. (301093.SZ): has repurchased 0.99% of shares to date.
On September 2nd, Gelonhui announced that as of August 31, 2024, the company has repurchased a total of 1,281,000 shares of the company through a dedicated securities account using its own funds and centralized bidding trading method, accounting for 0.99% of the total share capital. The highest purchase price was 20.164 yuan/share, the lowest price was 18.066 yuan/share, and the total amount paid was RMB 24,692,847.100 (excluding transaction fees). The progress of the repurchase complies with relevant laws and regulations and the company's share repurchase plan.
Hualan Co., Ltd.: Summary of the 2024 Semi-Annual Report
Hualan shares: 2024 semi-annual report
The Returns On Capital At Jiangsu Hualan New Pharmaceutical MaterialLtd (SZSE:301093) Don't Inspire Confidence
No Data
